-
1
-
-
84871995815
-
Standards of medical care in diabetes-2013
-
American Diabetes Association
-
American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66. American Diabetes Association.
-
(2013)
Diabetes Care
, vol.36
, Issue.SUPPL. 1
-
-
-
2
-
-
77953821528
-
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
-
Collaboration ERF, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingrlsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010, 375:2215-2222.
-
(2010)
Lancet
, vol.375
, pp. 2215-2222
-
-
Collaboration, E.R.F.1
Sarwar, N.2
Gao, P.3
Seshasai, S.R.4
Gobin, R.5
Kaptoge, S.6
Di Angelantonio, E.7
Ingrlsson, E.8
Lawlor, D.A.9
Selvin, E.10
Stampfer, M.11
Stehouwer, C.D.12
Lewington, S.13
Pennells, L.14
Thompson, A.15
Sattar, N.16
White, I.R.17
Ray, K.K.18
Danesh, J.19
-
3
-
-
84895816458
-
Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus
-
CD008143
-
Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterlev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013, 11. CD008143.
-
(2013)
Cochrane Database Syst Rev
, vol.11
-
-
Hemmingsen, B.1
Lund, S.S.2
Gluud, C.3
Vaag, A.4
Almdal, T.P.5
Hemmingsen, C.6
Wetterlev, J.7
-
4
-
-
68149170224
-
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
-
ADVANCE Collaborative Group
-
Ninomiya T, Perkovic V, De Galan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Machmahon S, Chalmers J, . ADVANCE Collaborative Group Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009, 20:1813-1821. ADVANCE Collaborative Group.
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 1813-1821
-
-
Ninomiya, T.1
Perkovic, V.2
De Galan, B.E.3
Zoungas, S.4
Pillai, A.5
Jardine, M.6
Patel, A.7
Cass, A.8
Neal, B.9
Poulter, N.10
Mogensen, C.E.11
Cooper, M.12
Marre, M.13
Williams, B.14
Hamet, P.15
Mancia, G.16
Woodward, M.17
Machmahon, S.18
Chalmers, J.19
-
5
-
-
79955752170
-
Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations
-
Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasingher P, Block L, Nicholson WK, Hutfless S, Bass EB, Bolen S. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.
-
(2011)
Ann Intern Med
, vol.154
, pp. 602-613
-
-
Bennett, W.L.1
Maruthur, N.M.2
Singh, S.3
Segal, J.B.4
Wilson, L.M.5
Chatterjee, R.6
Marinopoulos, S.S.7
Puhan, M.A.8
Ranasingher, P.9
Block, L.10
Nicholson, W.K.11
Hutfless, S.12
Bass, E.B.13
Bolen, S.14
-
6
-
-
84879324855
-
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial
-
Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013, 10:289-301.
-
(2013)
Diab Vasc Dis Res
, vol.10
, pp. 289-301
-
-
Rosenstock, J.1
Marx, N.2
Kahn, S.E.3
Zinman, B.4
Kastelein, J.J.5
Lachin, J.M.6
Bluhmki, E.7
Patel, S.8
Johansen, O.E.9
Woerle, H.J.10
-
7
-
-
0026061942
-
Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement
-
Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991, 121:1244-1263.
-
(1991)
Am Heart J
, vol.121
, pp. 1244-1263
-
-
Dzau, V.1
Braunwald, E.2
-
8
-
-
84890914711
-
Incorporating lag time to benefit into prevention decisions for older adults
-
Lee SJ, Leipzig RM. Incorporating lag time to benefit into prevention decisions for older adults. JAMA 2013, 310:2609-2610.
-
(2013)
JAMA
, vol.310
, pp. 2609-2610
-
-
Lee, S.J.1
Leipzig, R.M.2
-
9
-
-
72249116214
-
-
(accessed November 15, 2013), Food and Drug Administration (Center for Drug Evaluation and Research)
-
Food and Drug Administration (Center for Drug Evaluation and Research) Guidance for Industry: Diabetes Mellitus - Eevaluating Cardiovascular risk in New Antidiabetic Therapies to Treat Type 2 Diabetes 2008, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. (accessed November 15, 2013), Food and Drug Administration (Center for Drug Evaluation and Research).
-
(2008)
Guidance for Industry: Diabetes Mellitus - Eevaluating Cardiovascular risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
-
-
-
11
-
-
80052362968
-
Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes
-
Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011, 32:515-531.
-
(2011)
Endocr Rev
, vol.32
, pp. 515-531
-
-
Abdul-Ghani, M.A.1
Norton, L.2
DeFronzo, R.A.3
-
12
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
-
Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012, 14:83-90.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
Himmelsbach, F.4
Sauer, A.5
Sharp, D.E.6
Bakker, R.A.7
Mark, M.8
Klein, T.9
Eickelmann, P.10
-
13
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial
-
EMPA-REG METSU Trial Investigators
-
Häring H-U, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Woerle HJ, Broedl UC, . EMPA-REG METSU Trial Investigators Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 2013, 36:3396-3404. EMPA-REG METSU Trial Investigators.
-
(2013)
Diabetes Care
, vol.36
, pp. 3396-3404
-
-
Häring, H.-U.1
Merker, L.2
Seewaldt-Becker, E.3
Weimer, M.4
Meinicke, T.5
Woerle, H.J.6
Broedl, U.C.7
-
14
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
-
EMPA-REG PIO™ Trial Investigators
-
Kovacs CS, Seshiah V, Swallow R, Jones R, Rattunde H, Woerle HJ, Broedl UC, . EMPA-REG PIO™ Trial Investigators Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014, 16:147-158. EMPA-REG PIO™ Trial Investigators.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
Jones, R.4
Rattunde, H.5
Woerle, H.J.6
Broedl, U.C.7
-
15
-
-
84885954870
-
Empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator
-
EMPA-REG MONO Trial Investigators
-
Roden M, Weng J, Eilbracht J, Delafont B, Kim G, Woerle HJ, Broedl UC, . EMPA-REG MONO Trial Investigators Empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator. Lancet Diabetes Endocrinol 2013, 1:208-219. EMPA-REG MONO Trial Investigators.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 208-219
-
-
Roden, M.1
Weng, J.2
Eilbracht, J.3
Delafont, B.4
Kim, G.5
Woerle, H.J.6
Broedl, U.C.7
-
16
-
-
84892658063
-
Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension
-
Tikkanen I, Narko K, Zeller C, Green A, Salsali A, Broedl UC, Woerle HJ. Empagliflozin improves blood pressure in patients with type 2 diabetes (T2DM) and hypertension. Diabetologia 2013, 56(suppl 1):S377 [942].
-
(2013)
Diabetologia
, vol.56
, Issue.SUPPL. 1
-
-
Tikkanen, I.1
Narko, K.2
Zeller, C.3
Green, A.4
Salsali, A.5
Broedl, U.C.6
Woerle, H.J.7
-
17
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing anti-diabetes therapy in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
-
EMPA-REG RENAL Trial Investigators
-
Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC, . EMPA-REG RENAL Trial Investigators Efficacy and safety of empagliflozin added to existing anti-diabetes therapy in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014, 2:369-384. EMPA-REG RENAL Trial Investigators.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
Jones, R.4
Rattunde, H.5
Woerle, H.J.6
Broedl, U.C.7
-
18
-
-
84892959743
-
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
-
Cherney DZI, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, Von Eynatten M, Broedl UC. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014, 13:28.
-
(2014)
Cardiovasc Diabetol
, vol.13
, pp. 28
-
-
Cherney, D.Z.I.1
Perkins, B.A.2
Soleymanlou, N.3
Har, R.4
Fagan, N.5
Johansen, O.E.6
Woerle, H.J.7
Von Eynatten, M.8
Broedl, U.C.9
-
19
-
-
84893214045
-
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
-
Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan N, Woerle HJ, Johansen OE, Broedl UC, Von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014, 129:587-597.
-
(2014)
Circulation
, vol.129
, pp. 587-597
-
-
Cherney, D.Z.I.1
Perkins, B.A.2
Soleymanlou, N.3
Maione, M.4
Lai, V.5
Lee, A.6
Fagan, N.7
Woerle, H.J.8
Johansen, O.E.9
Broedl, U.C.10
Von Eynatten, M.11
-
20
-
-
84892479365
-
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
-
Bolinder J, Ljunggren T, Johansson L, Wilding J, Langkilde AM, Sjöström CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2014, 16:159-169.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 159-169
-
-
Bolinder, J.1
Ljunggren, T.2
Johansson, L.3
Wilding, J.4
Langkilde, A.M.5
Sjöström, C.D.6
Sugg, J.7
Parikh, S.8
-
21
-
-
84884167643
-
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
-
Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950.
-
(2013)
Lancet
, vol.382
, pp. 941-950
-
-
Cefalu, W.T.1
Leiter, L.A.2
Yoon, K.H.3
Arias, P.4
Niskanen, L.5
Xie, J.6
Balis, D.A.7
Canovatchel, W.8
Meininger, G.9
-
22
-
-
84876311251
-
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
-
Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, Figueroa K, Wajs E, Usiskin K, Meininger G. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 463-473
-
-
Yale, J.F.1
Bakris, G.2
Cariou, B.3
Yue, D.4
David-Neto, E.5
Xi, L.6
Figueroa, K.7
Wajs, E.8
Usiskin, K.9
Meininger, G.10
-
23
-
-
43649105816
-
Maintaining confidentiality of interim data to enhance trial integrity and credibility
-
Fleming T, Sharples K, McCall J, Moore A, Rodgers A, Stewart R. Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clinical Trials 2008, 5:157-167.
-
(2008)
Clinical Trials
, vol.5
, pp. 157-167
-
-
Fleming, T.1
Sharples, K.2
McCall, J.3
Moore, A.4
Rodgers, A.5
Stewart, R.6
-
24
-
-
84880924263
-
Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial
-
Neal B, Perkovic V, De Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, Shaw W, Jiang J, Vercruysse F, Meininger G, Matthews D. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebo-controlled trial. Am Heart J 2013, 166:217-223.
-
(2013)
Am Heart J
, vol.166
, pp. 217-223
-
-
Neal, B.1
Perkovic, V.2
De Zeeuw, D.3
Mahaffey, K.W.4
Fulcher, G.5
Stein, P.6
Desai, M.7
Shaw, W.8
Jiang, J.9
Vercruysse, F.10
Meininger, G.11
Matthews, D.12
-
25
-
-
84903277254
-
Sodium glucose cotransport-2 inhibition increases urinary ACE2 levels in patients with type 1 diabetes
-
Burns KD, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, Von Eynatten M, Cherney DZI. Sodium glucose cotransport-2 inhibition increases urinary ACE2 levels in patients with type 1 diabetes. Diabetes 2014, S1:543-P.
-
(2014)
Diabetes
, vol.S1
-
-
Burns, K.D.1
Perkins, B.A.2
Soleymanlou, N.3
Xiao, F.4
Zimpelmann, J.5
Woerle, H.J.6
Johansen, O.E.7
Broedl, U.C.8
Von Eynatten, M.9
Cherney, D.Z.I.10
-
26
-
-
84892588641
-
SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice
-
Vallon V, Gerasimova M, Rose MA, Masuda T, Satriano J, Mayoux E, Koepsell H, Thomson SC, Rieg T. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014, 306:F194-F204.
-
(2014)
Am J Physiol Renal Physiol
, vol.306
-
-
Vallon, V.1
Gerasimova, M.2
Rose, M.A.3
Masuda, T.4
Satriano, J.5
Mayoux, E.6
Koepsell, H.7
Thomson, S.C.8
Rieg, T.9
-
27
-
-
84899941589
-
Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal Phase III trials
-
Hach T, Gerich J, Salsali A, Kim G, Hantel S, Woerle HJ, Broedl UC. Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with type 2 diabetes (T2DM): pooled data from four pivotal Phase III trials. Diabetes 2013, 62(suppl 1A):LB19 [69-LB].
-
(2013)
Diabetes
, vol.62
, Issue.SUPPL. 1A
-
-
Hach, T.1
Gerich, J.2
Salsali, A.3
Kim, G.4
Hantel, S.5
Woerle, H.J.6
Broedl, U.C.7
-
28
-
-
84908503059
-
Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?
-
doi:10.1038/ki.2013.451 [Epub ahead of print]
-
Gilbert RE. Sodium-glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?. Kidney Int 2013, doi:10.1038/ki.2013.451 [Epub ahead of print].
-
(2013)
Kidney Int
-
-
Gilbert, R.E.1
|